Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer.
An economic sub-study was run alongside a large multi-centre randomised trial (MRC-CR06) comparing three chemotherapy regimens; de Gramont, Lokich and raltitrexed in patients with metastatic colorectal cancer. Patients in six of 45 centres in the main trial were approached to take part in the sub-st...
Principais autores: | Hale, J, Cohen, DR, Maughan, T, Stephens, R |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
2002
|
Registros relacionados
-
Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial.
por: Maughan, T, et al.
Publicado em: (2002) -
Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer
por: Moe, M, et al.
Publicado em: (2008) -
Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
por: Maughan, T, et al.
Publicado em: (2010) -
A cost comparison of biologic treatment regimens for metastatic colorectal cancer in Italy
por: Sergio Iannazzo, et al.
Publicado em: (2017-10-01) -
Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer.
por: Adriana Camargo Carvalho, et al.
Publicado em: (2017-01-01)